Carlos Navas
Research Subjects
Carlos Navas has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Casallas-Vanegas
Multiple Sclerosis and Demyelinating Disorders Clinic National Institute of Neurology and Neurosurgery Mexico City Mexico
1 shared publication - Ana Paula León
Centro de Innovación y Educación de Pacientes y Familias
1 shared publication - Andrea Hernandez
Clínica Universitaria Colombia - Department of Neuropediatrics - Bogotá D.C. - Colombia
1 shared publication Aurelio Mosquera
1 shared publication- Camilo Alberto González González
Departamento de Medicina Interna, Unidad de Nefrología Hospital Universitario San Ignacio Bogotá Colombia
1 shared publication - Cesar Augusto Franco Ruiz
Department of Neurology, Hospital Neurológico de Colombia, Medellín, Colombia
1 shared publication
Latest Publications
- 30 December 2025
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 16 (3) , 319-324
Multiple sclerosis expert patient program in Central America: changes in quality of life and lifestyle habits
To assess the impact of an Expert Patient Program on the quality of life and lifestyle habits of multiple sclerosis patients and their caregivers from Costa Rica, Honduras, and Dominican Republic. Quasi-experimental design, with repeated measures, without control group. The sessions taught self-care, problem-solving, nutrition, physical activity, fatigue, sleep, pain, and emotions. Data was collected using online questionnaires, such as the Short Version of the World Health Organization Quality of Life questionnaire. Data analysis included Student's t-test for related samples and Cohen's d. 65 cases, with 75.4% patients. Participants increased adherence to healthy lifestyle habits, physical activity, and reduced sedentarism. Those living with the disease for more than five years improved the physical (p = 0,019) and psychological domains (p = 0,008), while individuals with lower education levels improved their environmental domain (p = 0,005). This pilot study provides evidence supporting the impact of this Program on quality of life.
- 30 December 2025
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 16 (3) , 319-324
Multiple sclerosis expert patient program in Central America: changes in quality of life and lifestyle habits
To assess the impact of an Expert Patient Program on the quality of life and lifestyle habits of multiple sclerosis patients and their caregivers from Costa Rica, Honduras, and Dominican Republic. Quasi-experimental design, with repeated measures, without control group. The sessions taught self-care, problem-solving, nutrition, physical activity, fatigue, sleep, pain, and emotions. Data was collected using online questionnaires, such as the Short Version of the World Health Organization Quality of Life questionnaire. Data analysis included Student's t-test for related samples and Cohen's d. 65 cases, with 75.4% patients. Participants increased adherence to healthy lifestyle habits, physical activity, and reduced sedentarism. Those living with the disease for more than five years improved the physical (p = 0,019) and psychological domains (p = 0,008), while individuals with lower education levels improved their environmental domain (p = 0,005). This pilot study provides evidence supporting the impact of this Program on quality of life.
- Open Access
- 31 January 2025
- Published by Asociacion Colombiana de Neurologia in Acta Neurológica Colombiana
- Vol. 41 (1)
Fallo terapéutico en esclerosis múltiple remitente-recurrente: definición y algoritmo para su manejo, un consenso de expertos
Introducción: la esclerosis múltiple es una enfermedad crónica, neurodegenerativa y autoinmune del sistema nervioso central. En Colombia, se considera como la enfermedad huérfana-rara más común, con 3224 casos reportados entre los años 2016 y 2021. El tratamiento se basa en una variedad de terapias modificadoras de la enfermedad que busca reducir las recaídas, disminuir la actividad en imágenes y retrasar la progresión de la discapacidad; sin embargo, el manejo clínico presenta desafíos debido a la falta de definiciones claras sobre el fallo de las terapias modificadoras y la falta de guías claras para el cambio de tratamiento. Objetivo: elaborar una definición de fallo terapéutico y diseñar un algoritmo para su manejo en pacientes con esclerosis múltiple recurrente en Colombia. Materiales y métodos: se llevó a cabo un consenso de expertos mediante la metodología Delphi en dos rondas virtuales con diez expertos. Además, se hizo una revisión de la literatura para obtener información destinada al diseño de la definición y al algoritmo del fallo terapéutico. Resultados: se elaboró una definición de fallo terapéutico compuesta por una introducción y la descripción de las variables clínicas que se utilizarán para determinar si un paciente presenta fallo terapéutico, y también se diseñó un algoritmo con una estrategia de optimización terapéutica, considerando las necesidades individuales de cada paciente según la definición diseñada previamente. Conclusiones: se desarrolló una definición y un algoritmo de manejo específico para Colombia basados en evidencia, experiencia clínica y recomendaciones de expertos. Estas herramientas facilitarán la toma de decisiones, el seguimiento y la eficiencia de los tratamientos, y se actualizarán periódicamente para reflejar avances científicos y mejores prácticas.
- 31 January 2025
- Published by Asociacion Colombiana de Neurologia in Acta Neurológica Colombiana
- Vol. 41 (1)
Open AccessFallo terapéutico en esclerosis múltiple remitente-recurrente: definición y algoritmo para su manejo, un consenso de expertos
Introducción: la esclerosis múltiple es una enfermedad crónica, neurodegenerativa y autoinmune del sistema nervioso central. En Colombia, se considera como la enfermedad huérfana-rara más común, con 3224 casos reportados entre los años 2016 y 2021. El tratamiento se basa en una variedad de terapias modificadoras de la enfermedad que busca reducir las recaídas, disminuir la actividad en imágenes y retrasar la progresión de la discapacidad; sin embargo, el manejo clínico presenta desafíos debido a la falta de definiciones claras sobre el fallo de las terapias modificadoras y la falta de guías claras para el cambio de tratamiento. Objetivo: elaborar una definición de fallo terapéutico y diseñar un algoritmo para su manejo en pacientes con esclerosis múltiple recurrente en Colombia. Materiales y métodos: se llevó a cabo un consenso de expertos mediante la metodología Delphi en dos rondas virtuales con diez expertos. Además, se hizo una revisión de la literatura para obtener información destinada al diseño de la definición y al algoritmo del fallo terapéutico. Resultados: se elaboró una definición de fallo terapéutico compuesta por una introducción y la descripción de las variables clínicas que se utilizarán para determinar si un paciente presenta fallo terapéutico, y también se diseñó un algoritmo con una estrategia de optimización terapéutica, considerando las necesidades individuales de cada paciente según la definición diseñada previamente. Conclusiones: se desarrolló una definición y un algoritmo de manejo específico para Colombia basados en evidencia, experiencia clínica y recomendaciones de expertos. Estas herramientas facilitarán la toma de decisiones, el seguimiento y la eficiencia de los tratamientos, y se actualizarán periódicamente para reflejar avances científicos y mejores prácticas.
- 2 May 2022
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 28 (10) , 1498-1499
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes
- 2 May 2022
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 28 (10) , 1498-1499
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes
- 7 April 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (6) , 1274-1280
Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders
Background: Optic neuritis (ON) causes several sequela. Aggressive treatment with plasma exchange (TPE) is an option. This study describes improvement and safety outcomes with TPE.Methods: We recruited adults with ON in neuromyelitis optica spectrum disorders (NMOSD) patients treated with TPE. The primary outcome was an improvement in the visual acuity scale (VOS). We described the data and used multivariate logistic regression to identify factors associated with response.Results: Eighty‐three patients received 558 TPE sessions. Mean age was 40.9 years (±13.7 years); 73.5% were women, 50.1% were first attack, and 10.7% were bilateral. Median VOS: 5 (range [R], 2–7). Median time between onset and TPE was 8 days (R, 1–32). By Keegan's criteria, 82.4% experience improvement and 78.3% improve in at least 1 point in VOS. Age and pre‐TPE VOS were related to improvement. Low fibrinogen occurs in 26% sessions.Conclusion: TPE is effective and safety for ON in NMOSD patients. There is a need for a clinical trial using a therapeutic equivalent.
- 7 April 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (6) , 1274-1280
Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders
Background: Optic neuritis (ON) causes several sequela. Aggressive treatment with plasma exchange (TPE) is an option. This study describes improvement and safety outcomes with TPE.Methods: We recruited adults with ON in neuromyelitis optica spectrum disorders (NMOSD) patients treated with TPE. The primary outcome was an improvement in the visual acuity scale (VOS). We described the data and used multivariate logistic regression to identify factors associated with response.Results: Eighty‐three patients received 558 TPE sessions. Mean age was 40.9 years (±13.7 years); 73.5% were women, 50.1% were first attack, and 10.7% were bilateral. Median VOS: 5 (range [R], 2–7). Median time between onset and TPE was 8 days (R, 1–32). By Keegan's criteria, 82.4% experience improvement and 78.3% improve in at least 1 point in VOS. Age and pre‐TPE VOS were related to improvement. Low fibrinogen occurs in 26% sessions.Conclusion: TPE is effective and safety for ON in NMOSD patients. There is a need for a clinical trial using a therapeutic equivalent.
- Open Access
- 1 January 2019
- Published by Universidad Nacional de Colombia in Case reports
- Vol. 5 (1) , 11-18
Neuromyelitis optica spectrum disorder in pediatrics. Case report
Introduction: Neuromyelitis optica is an inflammatory disorder of the central nervous system that accounts for 5% of demyelinating diseases in pediatrics. Its clinical presentation is variable and associated to the involved area of the central nervous system.Case presentation: This is the case of a 15-year-old patient who consulted several times for nonspecific neurological symptoms. During his last visit to the Clínica Universitaria Colombia in Bogotá, he presented with bilateral optic neuritis, associated with frontal and parietal headache. Immunophenotyping studies were carried out, reporting positive IgG anti-aquaporin 4 antibodies (anti-AQP4 antibody), thus leading to a diagnosis of seropositive neuromyelitis optica spectrum disorder (NMOSD). Management with methylprednisolone pulses was initiated with subsequent outpatient management with rituximab that allowed stabilizing the disease.Discussion: This is an interesting case due to its insidious and uncertain onset in a pediatric patient. It was possible to evaluate clinical and diagnostic differences in relation to its presentation in adults. NMOSD mediated by anti-AQP4 is rare; brain and bone marrow MRI are essential for diagnosis. The treatment of choice for acute conditions consists of high doses of methylprednisolone.Conclusion: This disorder may result in irreversible neurological damage; for this reason, high suspicion is required for early diagnosis and timely treatment.
- 1 January 2019
- Published by Universidad Nacional de Colombia in Case reports
- Vol. 5 (1) , 11-18
Open AccessNeuromyelitis optica spectrum disorder in pediatrics. Case report
Introduction: Neuromyelitis optica is an inflammatory disorder of the central nervous system that accounts for 5% of demyelinating diseases in pediatrics. Its clinical presentation is variable and associated to the involved area of the central nervous system.Case presentation: This is the case of a 15-year-old patient who consulted several times for nonspecific neurological symptoms. During his last visit to the Clínica Universitaria Colombia in Bogotá, he presented with bilateral optic neuritis, associated with frontal and parietal headache. Immunophenotyping studies were carried out, reporting positive IgG anti-aquaporin 4 antibodies (anti-AQP4 antibody), thus leading to a diagnosis of seropositive neuromyelitis optica spectrum disorder (NMOSD). Management with methylprednisolone pulses was initiated with subsequent outpatient management with rituximab that allowed stabilizing the disease.Discussion: This is an interesting case due to its insidious and uncertain onset in a pediatric patient. It was possible to evaluate clinical and diagnostic differences in relation to its presentation in adults. NMOSD mediated by anti-AQP4 is rare; brain and bone marrow MRI are essential for diagnosis. The treatment of choice for acute conditions consists of high doses of methylprednisolone.Conclusion: This disorder may result in irreversible neurological damage; for this reason, high suspicion is required for early diagnosis and timely treatment.
- 1 January 2004
- Published by IMR Press in Revista De Neurologia
- Vol. 39 (04) , 301
Validación de un cuestionario para detección de ictus en poblaciones hispanoparlantes
- 1 January 2004
- Published by IMR Press in Revista De Neurologia
- Vol. 39 (04) , 301
Validación de un cuestionario para detección de ictus en poblaciones hispanoparlantes